Reagents (3)

RG108

Reference: SM31-2

€0.00 (tax incl.)

RG108 inhibits human tumor cell line (HCT116, NALM-6) proliferation and increased doubling time in culture.

RG108

Reference: SM31-10

€0.00 (tax incl.)

RG108 inhibits human tumor cell line (HCT116, NALM-6) proliferation and increased doubling time in culture.

RG108

Reference: SM31-50

€0.00 (tax incl.)

RG108 inhibits human tumor cell line (HCT116, NALM-6) proliferation and increased doubling time in culture.

Rosiglitazone is antidiabetic, working as an insulin sensitizer by binding to the PPAR gamma receptors in fat cells and making the cells more responsive to insulin. Rosiglitazone induced adipocyte differentiation in...

Rosiglitazone

Reference: SM86-50

€0.00 (tax incl.)

Rosiglitazone is antidiabetic, working as an insulin sensitizer by binding to the PPAR gamma receptors in fat cells and making the cells more responsive to insulin. Rosiglitazone induced adipocyte differentiation in...

Rosiglitazone

Reference: SM86-200

€0.00 (tax incl.)

Rosiglitazone is antidiabetic, working as an insulin sensitizer by binding to the PPAR gamma receptors in fat cells and making the cells more responsive to insulin. Rosiglitazone induced adipocyte differentiation in...

Rosiglitazone

Reference: SM86-1000

€0.00 (tax incl.)

Rosiglitazone is antidiabetic, working as an insulin sensitizer by binding to the PPAR gamma receptors in fat cells and making the cells more responsive to insulin. Rosiglitazone induced adipocyte differentiation in...

Ruxolitinib

Reference: SM87-2

€0.00 (tax incl.)

JAK inhibition with ruxolitinib could work as pretreatment for allogeneic stem cell transplantation in myelofibrosis. Ruxolitinib inhibits erythropoiesis from induced pluripotent stem cells (iPSC), but has less...

Ruxolitinib

Reference: SM87-10

€0.00 (tax incl.)

JAK inhibition with ruxolitinib could work as pretreatment for allogeneic stem cell transplantation in myelofibrosis. Ruxolitinib inhibits erythropoiesis from induced pluripotent stem cells (iPSC), but has less...

Ruxolitinib

Reference: SM87-25

€0.00 (tax incl.)

JAK inhibition with ruxolitinib could work as pretreatment for allogeneic stem cell transplantation in myelofibrosis. Ruxolitinib inhibits erythropoiesis from induced pluripotent stem cells (iPSC), but has less...

Ruxolitinib

Reference: SM87-100

€0.00 (tax incl.)

JAK inhibition with ruxolitinib could work as pretreatment for allogeneic stem cell transplantation in myelofibrosis. Ruxolitinib inhibits erythropoiesis from induced pluripotent stem cells (iPSC), but has less...

SAHA

Reference: SM88-10

€0.00 (tax incl.)

Experiments suggest that SAHA causes morphological changes, such as enlargement and flattening of the cytoplasm, resulting in growth inhibition. SAHA alters gene transcription and induces cell cycle arrest and/or...

SAHA

Reference: SM88-50

€0.00 (tax incl.)

Experiments suggest that SAHA causes morphological changes, such as enlargement and flattening of the cytoplasm, resulting in growth inhibition. SAHA alters gene transcription and induces cell cycle arrest and/or...

SAHA

Reference: SM88-250

€0.00 (tax incl.)

Experiments suggest that SAHA causes morphological changes, such as enlargement and flattening of the cytoplasm, resulting in growth inhibition. SAHA alters gene transcription and induces cell cycle arrest and/or...

SAHA

Reference: SM88-500

€0.00 (tax incl.)

Experiments suggest that SAHA causes morphological changes, such as enlargement and flattening of the cytoplasm, resulting in growth inhibition. SAHA alters gene transcription and induces cell cycle arrest and/or...

SAHA

Reference: SM88-1000

€0.00 (tax incl.)

Experiments suggest that SAHA causes morphological changes, such as enlargement and flattening of the cytoplasm, resulting in growth inhibition. SAHA alters gene transcription and induces cell cycle arrest and/or...

SB203580

Reference: SM32-2

€0.00 (tax incl.)

SB203580 inhibits the IL-2-induced proliferation of primary human T cells, murine CT6 T cells, or BAF F7 B cells with an IC50 of 3 - 5 μM. SB203580 suppresses the development of endometriosis by down-regulating...

SB203580

Reference: SM32-10

€0.00 (tax incl.)

SB203580 inhibits the IL-2-induced proliferation of primary human T cells, murine CT6 T cells, or BAF F7 B cells with an IC50 of 3 - 5 μM. SB203580 suppresses the development of endometriosis by down-regulating...

SB203580

Reference: SM32-50

€0.00 (tax incl.)

SB203580 inhibits the IL-2-induced proliferation of primary human T cells, murine CT6 T cells, or BAF F7 B cells with an IC50 of 3 - 5 μM. SB203580 suppresses the development of endometriosis by down-regulating...

SB203580

Reference: SM32-100

€0.00 (tax incl.)

SB203580 inhibits the IL-2-induced proliferation of primary human T cells, murine CT6 T cells, or BAF F7 B cells with an IC50 of 3 - 5 μM. SB203580 suppresses the development of endometriosis by down-regulating...

SB216763

Reference: SM90-2

€0.00 (tax incl.)

SB216763 protects both central and peripheral nervous system neurones in culture from death induced by reduced PI 3-kinase pathway activity. Treatment of primary neural progenitor cells with SB216763 resulted in an...

SB216763

Reference: SM90-10

€0.00 (tax incl.)

SB216763 protects both central and peripheral nervous system neurones in culture from death induced by reduced PI 3-kinase pathway activity. Treatment of primary neural progenitor cells with SB216763 resulted in an...

SB216763

Reference: SM90-25

€0.00 (tax incl.)

SB216763 protects both central and peripheral nervous system neurones in culture from death induced by reduced PI 3-kinase pathway activity. Treatment of primary neural progenitor cells with SB216763 resulted in an...

SB216763

Reference: SM90-50

€0.00 (tax incl.)

SB216763 protects both central and peripheral nervous system neurones in culture from death induced by reduced PI 3-kinase pathway activity. Treatment of primary neural progenitor cells with SB216763 resulted in an...

SB216763

Reference: SM90-200

€0.00 (tax incl.)

SB216763 protects both central and peripheral nervous system neurones in culture from death induced by reduced PI 3-kinase pathway activity. Treatment of primary neural progenitor cells with SB216763 resulted in an...

SB431542

Reference: SM33-2

€0.00 (tax incl.)

SB431542 suppresses TGF-β-induced proliferation of human osteosarcoma cells. SB431542 treatment of glioma cultures inhibited proliferation, TGF-β-mediated morphologic changes, and cellular motility. Small molecule...

SB431542

Reference: SM33-10

€0.00 (tax incl.)

SB431542 suppresses TGF-β-induced proliferation of human osteosarcoma cells. SB431542 treatment of glioma cultures inhibited proliferation, TGF-β-mediated morphologic changes, and cellular motility. Small molecule...

SB431542

Reference: SM33-50

€0.00 (tax incl.)

SB431542 suppresses TGF-β-induced proliferation of human osteosarcoma cells. SB431542 treatment of glioma cultures inhibited proliferation, TGF-β-mediated morphologic changes, and cellular motility. Small molecule...

SB431542

Reference: SM33-200

€0.00 (tax incl.)

SB431542 suppresses TGF-β-induced proliferation of human osteosarcoma cells. SB431542 treatment of glioma cultures inhibited proliferation, TGF-β-mediated morphologic changes, and cellular motility. Small molecule...

SB590885

Reference: SM48-1

€0.00 (tax incl.)

In melanoma and colorectal cancer cell lines with B-Raf V600E mutation, an effective inhibition of cell proliferation was achieved by using SB590885 at concentrations that blocked ERK phosphorylation.

SB590885

Reference: SM48-5

€0.00 (tax incl.)

In melanoma and colorectal cancer cell lines with B-Raf V600E mutation, an effective inhibition of cell proliferation was achieved by using SB590885 at concentrations that blocked ERK phosphorylation.

SB590885

Reference: SM48-50

€0.00 (tax incl.)

In melanoma and colorectal cancer cell lines with B-Raf V600E mutation, an effective inhibition of cell proliferation was achieved by using SB590885 at concentrations that blocked ERK phosphorylation.

Sorafenib

Reference: SM95-10

€0.00 (tax incl.)

Sorafenib has anti-tumor activity in HCC models may be attributed to inhibition of tumor angiogenesis (VEGFR and PDGFR) and direct effects on tumor cell proliferation/survival (Raf kinase signaling-dependent and...

Sorafenib

Reference: SM95-50

€0.00 (tax incl.)

Sorafenib has anti-tumor activity in HCC models may be attributed to inhibition of tumor angiogenesis (VEGFR and PDGFR) and direct effects on tumor cell proliferation/survival (Raf kinase signaling-dependent and...

Sorafenib

Reference: SM95-500

€0.00 (tax incl.)

Sorafenib has anti-tumor activity in HCC models may be attributed to inhibition of tumor angiogenesis (VEGFR and PDGFR) and direct effects on tumor cell proliferation/survival (Raf kinase signaling-dependent and...

Sorafenib

Reference: SM95-1000

€0.00 (tax incl.)

Sorafenib has anti-tumor activity in HCC models may be attributed to inhibition of tumor angiogenesis (VEGFR and PDGFR) and direct effects on tumor cell proliferation/survival (Raf kinase signaling-dependent and...

SP600125

Reference: SM41-2

€0.00 (tax incl.)

SP600125 blocks the activation and differentiation of primary human CD4 cell cultures. SP600125 has also been shown to prevent apoptosis in an array of cell types, and it inhibits autophagy in HeLa cells.

SP600125

Reference: SM41-10

€0.00 (tax incl.)

SP600125 blocks the activation and differentiation of primary human CD4 cell cultures. SP600125 has also been shown to prevent apoptosis in an array of cell types, and it inhibits autophagy in HeLa cells.

SP600125

Reference: SM41-50

€0.00 (tax incl.)

SP600125 blocks the activation and differentiation of primary human CD4 cell cultures. SP600125 has also been shown to prevent apoptosis in an array of cell types, and it inhibits autophagy in HeLa cells.

SP600125

Reference: SM41-100

€0.00 (tax incl.)

SP600125 blocks the activation and differentiation of primary human CD4 cell cultures. SP600125 has also been shown to prevent apoptosis in an array of cell types, and it inhibits autophagy in HeLa cells.

SP600125

Reference: SM41-300

€0.00 (tax incl.)

SP600125 blocks the activation and differentiation of primary human CD4 cell cultures. SP600125 has also been shown to prevent apoptosis in an array of cell types, and it inhibits autophagy in HeLa cells.

Stauprimide

Reference: SM96-1

€0.00 (tax incl.)

Stauprimide may be used to study the signaling involved in differentiation of ESC. It increased definitive endodermal markers but not markers for visceral/parietal endoderm or mesoderm. Stauprimide-differentiated...

Stauprimide

Reference: SM96-5

€0.00 (tax incl.)

Stauprimide may be used to study the signaling involved in differentiation of ESC. It increased definitive endodermal markers but not markers for visceral/parietal endoderm or mesoderm. Stauprimide-differentiated...

Stauprimide

Reference: SM96-100

€0.00 (tax incl.)

Stauprimide may be used to study the signaling involved in differentiation of ESC. It increased definitive endodermal markers but not markers for visceral/parietal endoderm or mesoderm. Stauprimide-differentiated...

Staurosporine

Reference: SM97-1

€0.00 (tax incl.)

Staurosporine has several effects on cell function, including interruption of cell-cell contacts, decreasing focal contact size, inducing epithelial to mesenchyme transition, and promoting cell differentiation....

Staurosporine

Reference: SM97-5

€0.00 (tax incl.)

Staurosporine has several effects on cell function, including interruption of cell-cell contacts, decreasing focal contact size, inducing epithelial to mesenchyme transition, and promoting cell differentiation....

Staurosporine

Reference: SM97-10

€0.00 (tax incl.)

Staurosporine has several effects on cell function, including interruption of cell-cell contacts, decreasing focal contact size, inducing epithelial to mesenchyme transition, and promoting cell differentiation....

Staurosporine

Reference: SM97-50

€0.00 (tax incl.)

Staurosporine has several effects on cell function, including interruption of cell-cell contacts, decreasing focal contact size, inducing epithelial to mesenchyme transition, and promoting cell differentiation....

StemRegenin 1

Reference: SM98-5

€0.00 (tax incl.)

StemRegenin 1 treatment accelerates the proliferation of CD34+ cells. Sequential co-culture with BMP-4, PGE2, and StemRegenin 1 leads to robust Macaca nemestrina iPSC hematopoietic progenitor cell formation. Culture...

StemRegenin 1

Reference: SM98-25

€0.00 (tax incl.)

StemRegenin 1 treatment accelerates the proliferation of CD34+ cells. Sequential co-culture with BMP-4, PGE2, and StemRegenin 1 leads to robust Macaca nemestrina iPSC hematopoietic progenitor cell formation. Culture...

StemRegenin 1

Reference: SM98-50

€0.00 (tax incl.)

StemRegenin 1 treatment accelerates the proliferation of CD34+ cells. Sequential co-culture with BMP-4, PGE2, and StemRegenin 1 leads to robust Macaca nemestrina iPSC hematopoietic progenitor cell formation. Culture...

StemRegenin 1

Reference: SM98-100

€0.00 (tax incl.)

StemRegenin 1 treatment accelerates the proliferation of CD34+ cells. Sequential co-culture with BMP-4, PGE2, and StemRegenin 1 leads to robust Macaca nemestrina iPSC hematopoietic progenitor cell formation. Culture...

SU5402

Reference: SM99-1

€0.00 (tax incl.)

SU5402 is used in an embryonic stem cells (ESC) culture method with three inhibitors (3i: SU5402 for FGFR, PD184352 for ERK, and CHIR99021 for GSK3). It has been showed that this 3i method is extremely instrumental in...

SU5402

Reference: SM99-5

€0.00 (tax incl.)

SU5402 is used in an embryonic stem cells (ESC) culture method with three inhibitors (3i: SU5402 for FGFR, PD184352 for ERK, and CHIR99021 for GSK3). It has been showed that this 3i method is extremely instrumental in...

SU5402

Reference: SM99-10

€0.00 (tax incl.)

SU5402 is used in an embryonic stem cells (ESC) culture method with three inhibitors (3i: SU5402 for FGFR, PD184352 for ERK, and CHIR99021 for GSK3). It has been showed that this 3i method is extremely instrumental in...

SU5402

Reference: SM99-50

€0.00 (tax incl.)

SU5402 is used in an embryonic stem cells (ESC) culture method with three inhibitors (3i: SU5402 for FGFR, PD184352 for ERK, and CHIR99021 for GSK3). It has been showed that this 3i method is extremely instrumental in...

SU6668

Reference: SM100-2

€0.00 (tax incl.)

SU6668 inhibits proliferation of HUVEC and NIH3T3 cells in-vitro and induces >75% growth inhibition against a broad range of tumor types. SU6668 shows antiangiogenic, anti-inflammatory, antimetastatic and proapototic...

SU6668

Reference: SM100-10

€0.00 (tax incl.)

SU6668 inhibits proliferation of HUVEC and NIH3T3 cells in-vitro and induces >75% growth inhibition against a broad range of tumor types. SU6668 shows antiangiogenic, anti-inflammatory, antimetastatic and proapototic...

SU6668

Reference: SM100-50

€0.00 (tax incl.)

SU6668 inhibits proliferation of HUVEC and NIH3T3 cells in-vitro and induces >75% growth inhibition against a broad range of tumor types. SU6668 shows antiangiogenic, anti-inflammatory, antimetastatic and proapototic...

SU6668

Reference: SM100-200

€0.00 (tax incl.)

SU6668 inhibits proliferation of HUVEC and NIH3T3 cells in-vitro and induces >75% growth inhibition against a broad range of tumor types. SU6668 shows antiangiogenic, anti-inflammatory, antimetastatic and proapototic...

Sunitinib

Reference: SM101-10

€0.00 (tax incl.)

Sunitinib has been shown to impinge on the osteoblast differentiation process in-vitro. It exhibits antiangiogenic and antitumor activity in multiple xenograft models.

Sunitinib

Reference: SM101-50

€0.00 (tax incl.)

Sunitinib has been shown to impinge on the osteoblast differentiation process in-vitro. It exhibits antiangiogenic and antitumor activity in multiple xenograft models.

Sunitinib

Reference: SM101-300

€0.00 (tax incl.)

Sunitinib has been shown to impinge on the osteoblast differentiation process in-vitro. It exhibits antiangiogenic and antitumor activity in multiple xenograft models.

Sunitinib

Reference: SM101-500

€0.00 (tax incl.)

Sunitinib has been shown to impinge on the osteoblast differentiation process in-vitro. It exhibits antiangiogenic and antitumor activity in multiple xenograft models.

Sunitinib

Reference: SM101-1000

€0.00 (tax incl.)

Sunitinib has been shown to impinge on the osteoblast differentiation process in-vitro. It exhibits antiangiogenic and antitumor activity in multiple xenograft models.

Tandutinib

Reference: SM102-10

€0.00 (tax incl.)

Tandutinib inhibits cellular proliferation and induces apoptosis. Tandutinib works as a stem-like cells targeted agent to increase efficiency of anticancer drugs and it has antineoplastic activity.

Tandutinib

Reference: SM102-50

€0.00 (tax incl.)

Tandutinib inhibits cellular proliferation and induces apoptosis. Tandutinib works as a stem-like cells targeted agent to increase efficiency of anticancer drugs and it has antineoplastic activity.

Tandutinib

Reference: SM102-100

€0.00 (tax incl.)

Tandutinib inhibits cellular proliferation and induces apoptosis. Tandutinib works as a stem-like cells targeted agent to increase efficiency of anticancer drugs and it has antineoplastic activity.

TG101348

Reference: SM103-1

€0.00 (tax incl.)

TG101348 exhibits promising pharmacokinetic profiles. TG101348 inhibits erythropoiesis from induced pluripotent stem cells (iPSC), but has less inhibitory effect on the self-renewal of CD34+ hematopoietic progenitors.

TG101348

Reference: SM103-5

€0.00 (tax incl.)

TG101348 exhibits promising pharmacokinetic profiles. TG101348 inhibits erythropoiesis from induced pluripotent stem cells (iPSC), but has less inhibitory effect on the self-renewal of CD34+ hematopoietic progenitors.

TG101348

Reference: SM103-10

€0.00 (tax incl.)

TG101348 exhibits promising pharmacokinetic profiles. TG101348 inhibits erythropoiesis from induced pluripotent stem cells (iPSC), but has less inhibitory effect on the self-renewal of CD34+ hematopoietic progenitors.

TG101348

Reference: SM103-50

€0.00 (tax incl.)

TG101348 exhibits promising pharmacokinetic profiles. TG101348 inhibits erythropoiesis from induced pluripotent stem cells (iPSC), but has less inhibitory effect on the self-renewal of CD34+ hematopoietic progenitors.

Thiazovivin

Reference: SM35-2

€0.00 (tax incl.)

Thiazovivin protects human embryonic stem cells (hESC) in the absence of ECM by regulating E-cadherin mediated cell-cell interaction. Thiazovivin also promotes single cell passage of human pluripotent cells.

Thiazovivin

Reference: SM35-10

€0.00 (tax incl.)

Thiazovivin protects human embryonic stem cells (hESC) in the absence of ECM by regulating E-cadherin mediated cell-cell interaction. Thiazovivin also promotes single cell passage of human pluripotent cells.

Thiazovivin

Reference: SM35-50

€0.00 (tax incl.)

Thiazovivin protects human embryonic stem cells (hESC) in the absence of ECM by regulating E-cadherin mediated cell-cell interaction. Thiazovivin also promotes single cell passage of human pluripotent cells.

Trichostatin A

Reference: SM36-1

€0.00 (tax incl.)

HDAC is overexpressed in a variety of cancers and is closely correlated with oncogenic factors.

Trichostatin A

Reference: SM36-5

€0.00 (tax incl.)

HDAC is overexpressed in a variety of cancers and is closely correlated with oncogenic factors.

Trichostatin A

Reference: SM36-25

€0.00 (tax incl.)

HDAC is overexpressed in a variety of cancers and is closely correlated with oncogenic factors.

TWS119

Reference: SM105-2

€0.00 (tax incl.)

TWS119 induces neuronal differentiation in pluripotent murine embryonal carcinoma cells and embryonic stem cells (ESC). Because neuronal differentiation can be achieved without embryoid bodies (EB) formation and RA...

TWS119

Reference: SM105-10

€0.00 (tax incl.)

TWS119 induces neuronal differentiation in pluripotent murine embryonal carcinoma cells and embryonic stem cells (ESC). Because neuronal differentiation can be achieved without embryoid bodies (EB) formation and RA...

TWS119

Reference: SM105-25

€0.00 (tax incl.)

TWS119 induces neuronal differentiation in pluripotent murine embryonal carcinoma cells and embryonic stem cells (ESC). Because neuronal differentiation can be achieved without embryoid bodies (EB) formation and RA...

TWS119

Reference: SM105-50

€0.00 (tax incl.)

TWS119 induces neuronal differentiation in pluripotent murine embryonal carcinoma cells and embryonic stem cells (ESC). Because neuronal differentiation can be achieved without embryoid bodies (EB) formation and RA...

U0126

Reference: SM106-5

€0.00 (tax incl.)

Inhibition of MEK/ERK activity by specific MEK inhibitors PD98059 and U0126 rapidly causes the loss of human embryonic stem cells (hESC) pluripotency, acting as a promoter of hESC differentiation. U0126 is also useful...

U0126

Reference: SM106-25

€0.00 (tax incl.)

Inhibition of MEK/ERK activity by specific MEK inhibitors PD98059 and U0126 rapidly causes the loss of human embryonic stem cells (hESC) pluripotency, acting as a promoter of hESC differentiation. U0126 is also useful...

U0126

Reference: SM106-100

€0.00 (tax incl.)

Inhibition of MEK/ERK activity by specific MEK inhibitors PD98059 and U0126 rapidly causes the loss of human embryonic stem cells (hESC) pluripotency, acting as a promoter of hESC differentiation. U0126 is also useful...

U0126

Reference: SM106-300

€0.00 (tax incl.)

Inhibition of MEK/ERK activity by specific MEK inhibitors PD98059 and U0126 rapidly causes the loss of human embryonic stem cells (hESC) pluripotency, acting as a promoter of hESC differentiation. U0126 is also useful...

Vandetanib

Reference: SM107-2

€0.00 (tax incl.)

Vandetanib has been shown to influence in the osteoblast differentiation process in-vitro.

Vandetanib

Reference: SM107-25

€0.00 (tax incl.)

Vandetanib has been shown to influence in the osteoblast differentiation process in-vitro.

Vandetanib

Reference: SM107-100

€0.00 (tax incl.)

Vandetanib has been shown to influence in the osteoblast differentiation process in-vitro.

Vandetanib

Reference: SM107-500

€0.00 (tax incl.)

Vandetanib has been shown to influence in the osteoblast differentiation process in-vitro.